A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection

Trial Profile

A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Aflibercept (Primary) ; Cetuximab; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CALIVER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2017 Status changed from recruiting to discontinued.
    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top